Literature DB >> 27238842

Synthesis, biological evaluation, and physicochemical property assessment of 4-substituted 2-phenylaminoquinazolines as Mer tyrosine kinase inhibitors.

Sheng-Biao Wang1, Mu-Tian Cui1, Xiao-Feng Wang2, Emika Ohkoshi3, Masuo Goto3, De-Xuan Yang4, Linna Li4, Shoujun Yuan4, Susan L Morris-Natschke3, Kuo-Hsiung Lee5, Lan Xie6.   

Abstract

Current results identified 4-substituted 2-phenylaminoquinazoline compounds as novel Mer tyrosine kinase (Mer TK) inhibitors with a new scaffold. Twenty-one 2,4-disubstituted quinazolines (series 4-7) were designed, synthesized, and evaluated against Mer TK and a panel of human tumor cell lines aimed at exploring new Mer TK inhibitors as novel potential antitumor agents. A new lead, 4b, was discovered with a good balance between high potency (IC50 0.68μM) in the Mer TK assay and antiproliferative activity against MV4-11 (GI50 8.54μM), as well as other human tumor cell lines (GI50<20μM), and a desirable druglike property profile with low logP value (2.54) and high aqueous solubility (95.6μg/mL). Molecular modeling elucidated an expected binding mode of 4b with Mer TK and necessary interactions between them, thus supporting the hypothesis that Mer TK might be a biologic target of this kind of new active compound.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  4-Substituted 2-phenylaminoquinazolines; Antiproliferative; Mer tyrosine kinase inhibitors; Molecular modeling; Physicochemical properties

Mesh:

Substances:

Year:  2016        PMID: 27238842      PMCID: PMC4920374          DOI: 10.1016/j.bmc.2016.05.025

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  21 in total

1.  Mer receptor tyrosine kinase signaling: prevention of apoptosis and alteration of cytoskeletal architecture without stimulation or proliferation.

Authors:  Katherine L Guttridge; J Christopher Luft; Thomas L Dawson; Eva Kozlowska; Nupam P Mahajan; Brian Varnum; H Shelton Earp
Journal:  J Biol Chem       Date:  2002-04-02       Impact factor: 5.157

2.  Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Douglas K Graham; Dana B Salzberg; Joanne Kurtzberg; Susan Sather; Glenn K Matsushima; Amy K Keating; Xiayuan Liang; Mark A Lovell; Sara A Williams; Thomas L Dawson; Michael J Schell; Adil A Anwar; H Ralph Snodgrass; H Shelton Earp
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

3.  Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase.

Authors:  A K Keating; D B Salzberg; S Sather; X Liang; S Nickoloff; A Anwar; D Deryckere; K Hill; D Joung; K K Sawczyn; J Park; D Curran-Everett; L McGavran; L Meltesen; L Gore; G L Johnson; D K Graham
Journal:  Oncogene       Date:  2006-05-01       Impact factor: 9.867

4.  Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach.

Authors:  Rogier A Smits; Iwan J P de Esch; Obbe P Zuiderveld; Joachim Broeker; Kamonchanok Sansuk; Elena Guaita; Gabriella Coruzzi; Maristella Adami; Eric Haaksma; Rob Leurs
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

Review 5.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

Authors:  Rachel M A Linger; Amy K Keating; H Shelton Earp; Douglas K Graham
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

6.  The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity.

Authors:  Peter Houghton; Rui Fang; Isariya Techatanawat; Glyn Steventon; Peter J Hylands; C C Lee
Journal:  Methods       Date:  2007-08       Impact factor: 3.608

Review 7.  Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group.

Authors:  Maura O'Leary; Mark Krailo; James R Anderson; Gregory H Reaman
Journal:  Semin Oncol       Date:  2008-10       Impact factor: 4.929

8.  Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.

Authors:  Kirk R Schultz; W Paul Bowman; Alexander Aledo; William B Slayton; Harland Sather; Meenakshi Devidas; Chenguang Wang; Stella M Davies; Paul S Gaynon; Michael Trigg; Robert Rutledge; Laura Burden; Dean Jorstad; Andrew Carroll; Nyla A Heerema; Naomi Winick; Michael J Borowitz; Stephen P Hunger; William L Carroll; Bruce Camitta
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

9.  Structural insights into the inhibited states of the Mer receptor tyrosine kinase.

Authors:  Xudong Huang; Patrick Finerty; John R Walker; Christine Butler-Cole; Masoud Vedadi; Matthieu Schapira; Sirlester A Parker; Benjamin E Turk; Debra A Thompson; Sirano Dhe-Paganon
Journal:  J Struct Biol       Date:  2008-11-05       Impact factor: 2.867

10.  Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.

Authors:  W L Salzer; M Devidas; W L Carroll; N Winick; J Pullen; S P Hunger; B A Camitta
Journal:  Leukemia       Date:  2009-12-17       Impact factor: 11.528

View more
  1 in total

1.  Molecular dynamics, MMGBSA, and docking studies of natural products conjugated to tumor-targeted peptide for targeting BRAF V600E and MERTK receptors.

Authors:  Dominic J Lambo; Charlotta G Lebedenko; Paige A McCallum; Ipsita A Banerjee
Journal:  Mol Divers       Date:  2022-05-03       Impact factor: 2.943

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.